Morbelli Silvia, Bauckneht Matteo, Scheltens Philip
Unit of Nuclear Medicine, San Martino Polyclinic Hospital, Genoa, Italy -
Department of Health Sciences (DiSSAL), University of Genoa, Genoa, Italy -
Q J Nucl Med Mol Imaging. 2017 Dec;61(4):360-371. doi: 10.23736/S1824-4785.17.03011-4. Epub 2017 Jul 27.
Over the last 20 years the availability of magnetic resonance imaging and positron-emission tomography technologies as well as of cerebrospinal fluid biomarkers has allowed research and clinical approach to Alzheimer's disease (AD) to move towards the earliest manifestations of the disease. This new approach resulted in an increasing knowledge about in-vivo biological and neuropathological processes of each phase of the AD-related damage from preclinical, to mild cognitive impairment, and finally to dementia due to AD. The present narrative review deals with the available data as well as with the unsolved issued related to the incorporation of AD biomarkers into the clinical practice. Ongoing research efforts aiming to better define and implement the use of imaging AD biomarkers in clinical practice according to a patient-centered approach and sustainability for clinical-care systems are also discussed.
在过去20年里，磁共振成像、正电子发射断层扫描技术以及脑脊液生物标志物的出现，使得针对阿尔茨海默病（AD）的研究和临床方法能够朝着该疾病的最早表现发展。这种新方法使人们对AD相关损害从临床前阶段到轻度认知障碍，最终到AD所致痴呆的每个阶段的体内生物学和神经病理学过程有了越来越多的了解。本叙述性综述涉及现有数据以及与将AD生物标志物纳入临床实践相关的未解决问题。还讨论了正在进行的研究工作，旨在根据以患者为中心的方法以及临床护理系统的可持续性，更好地定义和实施成像AD生物标志物在临床实践中的应用。
